185 related articles for article (PubMed ID: 22225675)
21. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
[TBL] [Abstract][Full Text] [Related]
22. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
[TBL] [Abstract][Full Text] [Related]
23. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.
Naumann M; Dressler D; Hallett M; Jankovic J; Schiavo G; Segal KR; Truong D
Toxicon; 2013 Jun; 67():141-52. PubMed ID: 23178324
[TBL] [Abstract][Full Text] [Related]
24. Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.
Nestor M; Ablon G; Pickett A
Aesthet Surg J; 2017 May; 37(suppl_1):S20-S31. PubMed ID: 28388717
[TBL] [Abstract][Full Text] [Related]
25. Clinical resistance to three types of botulinum toxin type A in aesthetic medicine.
Stephan F; Habre M; Tomb R
J Cosmet Dermatol; 2014 Dec; 13(4):346-8. PubMed ID: 25399628
[TBL] [Abstract][Full Text] [Related]
26. Update on botulinum neurotoxin use in aesthetic dermatology.
Ibrahim O; Keller EC; Arndt KA
Semin Cutan Med Surg; 2014 Dec; 33(4):152-6. PubMed ID: 25830246
[TBL] [Abstract][Full Text] [Related]
27. Compositional differences among commercially available botulinum toxin type A.
Bakshi E; Hartstein ME
Curr Opin Ophthalmol; 2011 Sep; 22(5):407-12. PubMed ID: 21825992
[TBL] [Abstract][Full Text] [Related]
28. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
[TBL] [Abstract][Full Text] [Related]
29. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
[TBL] [Abstract][Full Text] [Related]
30. Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies.
Cavallini M; Cirillo P; Fundarò SP; Quartucci S; Sciuto C; Sito G; Tonini D; Trocchi G; Signorini M
Dermatol Surg; 2014 May; 40(5):525-36. PubMed ID: 24575858
[TBL] [Abstract][Full Text] [Related]
31. IncobotulinumtoxinA for Aesthetic Indications: A Systematic Review of Prospective Comparative Trials.
Prager W; Nogueira Teixeira D; Leventhal PS
Dermatol Surg; 2017 Jul; 43(7):959-966. PubMed ID: 28375973
[TBL] [Abstract][Full Text] [Related]
32. Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview.
Rzany B; Ascher B; Monheit G
J Eur Acad Dermatol Venereol; 2010 Jan; 24 Suppl 1():1-14. PubMed ID: 19930409
[TBL] [Abstract][Full Text] [Related]
33. Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
Rivers JK; Bertucci V; McGillivray W; Muhn C; Rosen N; Solish N; Weichman BM; Wheeler S; Daniels SR; Gallagher CJ
Dermatol Surg; 2015 Aug; 41(8):950-9. PubMed ID: 26218728
[TBL] [Abstract][Full Text] [Related]
34. Improving consent procedures and evaluation of treatment success in cosmetic use of incobotulinumtoxinA: an assessment of the treat-to-goal approach.
Jandhyala R
J Drugs Dermatol; 2013 Jan; 12(1):72-8. PubMed ID: 23377331
[TBL] [Abstract][Full Text] [Related]
35. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
[TBL] [Abstract][Full Text] [Related]
36. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.
Ascher B; Rzany BJ; Grover R
Dermatol Surg; 2009 Oct; 35(10):1478-86. PubMed ID: 19686365
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the spread of three botulinum toxin type A preparations.
Kerscher M; Roll S; Becker A; Wigger-Alberti W
Arch Dermatol Res; 2012 Mar; 304(2):155-61. PubMed ID: 22002325
[TBL] [Abstract][Full Text] [Related]
39. Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles.
Michaels BM; Csank GA; Ryb GE; Eko FN; Rubin A
Aesthet Surg J; 2012 Jan; 32(1):96-102. PubMed ID: 22231417
[TBL] [Abstract][Full Text] [Related]
40. Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.
Carruthers A; Sadick N; Brandt F; Trindade de Almeida AR; Fagien S; Goodman GJ; Raspaldo H; Smith K; Darmody S; Gallagher CJ; Street J; Romagnano L
Dermatol Surg; 2015 Jun; 41(6):693-701. PubMed ID: 25973559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]